NCT03027128View on ClinicalTrials.gov

QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

May 6, 2019

Study Completion Date

May 6, 2019

Conditions
Solid Tumor
Interventions
BIOLOGICAL

haNK™ for Infusion

haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).

Trial Locations (1)

90245

Chan Soon-Shiong Institute for Medicine, El Segundo

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY